Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial

Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial
Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma in a Phase 1 clinical trial. Mersana Therapeutics’ XMT-1536 is an antibody-drug conjugate that works by delivering a toxic compound specifically to cancer cells containing a protein called sodium-dependent phosphate transport protein 2b (NaPi2b). It is based on the company’s Dolaflexin platform,which has been designed to increase the safety, tolerability, and efficacy of antibody-drug-conjugates. Dolaflexin uses Fleximer, a biodegradable polymer (a large molecule made of repeated subunits) that links the antibody to the toxic compound. The polymer is intended to carry high amounts of this compound to kill cancer cells more efficiently. Mersana launched the Phase 1 trial (NCT03319628) in 2017 to test the experimental therapy. The trial, which is still recruiting patients at several sites across the U.S., is evaluating the safety and preliminary efficacy of XMT-1536 in adults with ovarian cancer or NSCLC adenocarcinoma, whose tumors likely contain NaPi2b. An initial dose-escalation phase is intended to determine the maximum tolerated or optimal recommended dose of XMT-1536. Then, an expansion phase will divide participants into two groups (one for those with ovarian cancer and another for those with NSCLC adenocarcinoma). XMT-1536 will be given at the dose determined previously to evaluate treatment response. XMT-1536 isadministered by intravenous (into-the-vein) infusion once every 28 days, until disease progression, unacceptable toxicity, or the patient or study physician decides to stop treatment. Of the 59 patients enrolled so far, 37 were diagnosed with ovarian cance
Subscribe or to access all post and page content.